Brind.

FibroGen received positive feedback from the FDA on a Type C meeting and increased the transaction consideration for the sale of FibroGen China.

1 report, 1 independent Updated Aug 12

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA China FibroGen (United States)

How it developed

Newest first. Tap a step to see who reported it.

Jun 7Positive Type C meeting supports advancement of roxadustat.Sub-event
Aug 12FibroGen secured a positive FDA Type C meeting and updated the sale consideration for its China assets.1 source
- GuruFocus.com

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
- The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49
- The Middle Corridor, linking Central Asia and Europe, is gaining significance in regional trade and energy routes.Mon 17:06
FibroGen (United States)
company in San Francisco, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 12GuruFocus.comFibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... Total Revenue: $1.3 million for Q2 2025, compared to $1 million for Q2 2024. Revenue Guidance: Full year